icometrix is set to be acquired by GE HealthCare, enhancing its AI-driven solutions for neurological care.

Target Company Overview

icometrix, a Belgium-based company specializing in AI-powered brain imaging analysis, is a portfolio company of Forestay Capital. Founded in 2011, icometrix has established itself as a global leader in the field, primarily through its flagship platform, icobrain. This platform provides a robust suite of AI-driven tools designed to analyze neurological diseases, which has positioned the company at the forefront of personalized treatment for conditions such as Alzheimer's disease, multiple sclerosis, and traumatic brain injury.

A notable innovation from icometrix is icobrain aria, recognized as the first FDA-cleared AI solution that detects side effects from amyloid-targeting therapies for Alzheimer’s. The company has continuously demonstrated its commitment to advancing brain health through cutting-edge technology and has received significant backing from prominent investors, contributing to its growth trajectory since its inception.

Industry Overview in Belgium

The healthcare and biotechnology sectors in Belgium have seen remarkable growth in recent years, primarily driven by innovations in medical technology and pharmaceuticals. Belgium is home to a dense cluster of healthcare companies and research